99358-09-5

Usage

Uses

Used in Pharmaceutical Industry:
7-AMINO-2,3-DIHYDRO-BENZO[1,4]DIOXINE-6-CARBOXYLIC ACID is used as a key intermediate for the synthesis of various pharmaceuticals due to its ability to form diverse chemical bonds and participate in multiple reactions. Its structural properties make it a valuable tool for the discovery and development of new chemical entities, contributing to the advancement of medicine.
Used in Agrochemical Industry:
In the agrochemical field, 7-AMINO-2,3-DIHYDRO-BENZO[1,4]DIOXINE-6-CARBOXYLIC ACID serves as a crucial component in the development of new agrochemicals. Its versatility in forming chemical bonds allows for the creation of innovative compounds that can address various agricultural needs, such as pest control and crop protection.
Used as a Chemical Intermediate:
7-AMINO-2,3-DIHYDRO-BENZO[1,4]DIOXINE-6-CARBOXYLIC ACID is utilized as a chemical intermediate in the synthesis of complex organic molecules. Its presence in the molecular structure facilitates the formation of desired products, making it an essential component in various chemical processes.

InChI:InChI=1/C9H9NO4/c10-6-4-8-7(13-1-2-14-8)3-5(6)9(11)12/h3-4H,1-2,10H2,(H,11,12)

Upstream product

• 57672-33-0 4,5-(ethylenedioxy)-2-nitrobenzoic acid 
• 2879-20-1 1,4-benzodioxan-6-yl methyl ketone 
• 4442-54-0 2,3-dihydro-1,4-benzodioxin-6-carboxylic acid 
• 2150-43-8 3,4-dihydroxybenzoic acid methyl ester 
• 99-50-3 3,4-Dihydroxybenzoic acid 
• 20197-76-6 7-amino-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid methyl ester 
• 20197-75-5 2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid methyl ester 
• 52791-03-4 7-nitro-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid methyl ester 
• 493-09-4 benzo-1,4-dioxane 

Downstream Products

• 52791-05-6 4-chloro-7,8-dihydro[1,4]-dioxino[2,3-g]quinazoline 
• 52791-04-5 3,4,7,8-tetrahydro[1,4]dioxino[2,3-g]quinazolin-4-one 

Relevant academic research and scientific papers

BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS

The present invention provides compounds and pharmaceutical compositions including the compounds for the treatment of a skin disease associated with proteolytic activity of one or more KLK proteases, wherein the compounds are according to formula (I): whe

As the PI3K/mTOR inhibitor tricyclic compound, its preparation and use

The invention discloses a tricyclic compound as a PI3K/mTOR inhibitor. The tricyclic compound is a compound with the general formula (I) in the specification, wherein Ar is selected from aryl or heteroaryl; X, Y and Z are independently selected from O, CR2R3 and NR4 respectively; Q is selected from O, CR2R3 and NR4 or does not exists; R1 represents C1-C6 alkyl; n is selected from integers from 0 to 4; when n is more than or equal to 2, two R1 and a morpholine cycle can be combined into a combined cycle, a bridge cycle or a spiral cycle; R2 and R3 are selected from hydrogen and C1-C6 alkyl; R4 is selected from hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, heterocyclic radical, acyl and sulfonyl. The invention further discloses a perpetration method of the compound with the general formula (I) as well as a pharmaceutical composition and application of the compound with the general formula (I).

Molecular features of the prazosin molecule required for activation of Transport-P

Closely related structural analogues of prazosin have been synthesised and tested for inhibition and activation of Transport-P in order to identify the structural features of the prazosin molecule that appear to be necessary for activation of Transport-P. So far, all the compounds tested are less active than prazosin. It is shown that the structure of prazosin appears to be very specific for the activation. Only quinazolines have been found to activate, and the presence of the 6,7-dimethoxy and 4-amino groups appears to be critically important.